Specific Anticonvulsants Increase Suicide Risk

A large-scale Harvard meta-analysis published in the Journal of the American Medical Association, is the first ever to evaluate the relationship between different anticonvulsant drugs and the risk of suicide in for patients with diverse diagnoses: " the risk was derived from the specific drug that the patient was taking and not their underlying conditions." Continue reading →

Did regulators fail over SSRIs? BMJ

Dr. David Healy, a formidable critic of the iron grip pharmaceutical corporations wield on the practice of psychiatry as well as on psychiatry’s deficient journal reports, directs his criticism at drug regulators in an article in the current British Medical Journal (BMJ). Continue reading →

Comparison of Suicide Rates in Treated Schizophrenia Patients Found 20-Fold Increase

An analysis published in the current issue of the British J of Psychiatry (BJP)  of the suicide rate among schizophrenia patients treated at the same hospital in North Wales (UK) before psychotropic drugs and patients treated (in and out of hospital) with neuroleptics and /or atypical antipsychotics, found a 20-fold increase in the suicide rate since use of psychotropic drugs. 

Continue reading →

FDA: NIMH SSRI Study Flawed–No Comparative Untreated Group

Even Dr. Robet Temple, FDA Medical Policy Director of the Center for Drug Evaluation & Research dismisses the claimed finidings of a flawed, but highly trumpeted recent SSRI study published in the American Journal of Psychiatry.  The study was sponsored by the National Institute of Mental Health.
Continue reading →